Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

THOMAS J GEORGE

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1104867365
CMS profile
321938
Location
GAINESVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$299.42

5 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $299.42 5

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $134.70 1
MAYNE PHARMA COMMERCIAL LLC $71.70 2
Genentech, Inc. $69.96 1
Evofem Biosciences, Inc. $23.06 1

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

THOMAS J GEORGE

NPI 1104867365 · CMS profile ID 321938

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

GAINESVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1104867365?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
THOMAS J GEORGE, NPI 1104867365, CMS profile ID 321938. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1104867365?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). THOMAS J GEORGE, NPI 1104867365, CMS profile ID 321938. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1104867365?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
THOMAS J GEORGE, NPI 1104867365, CMS profile ID 321938, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1104867365?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

5 matching records · $299.42 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 5 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–5 of 5.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Evofem Biosciences, Inc. $23.0608/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 976107295 CMS
MAYNE PHARMA COMMERCIAL LLC $37.1607/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060835327 CMS
Genentech, Inc. $69.9606/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040579939 CMS
MAYNE PHARMA COMMERCIAL LLC $34.5402/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060835325 CMS
AstraZeneca Pharmaceuticals LP $134.7001/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025024287 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,139.61 16
PY2020 $806.00 2
PY2021 $5,850.00 2
PY2022 $5,602.52 7
PY2023 $299.42 5
PY2024 $1,820.00 3
PY2025 $2,260.64 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $507,584.60 83
PY2024 Recipient $2,598.05 11
PY2024 Principal investigator $596,039.96 28
PY2023 Principal investigator $1,130,234.11 90
PY2022 Principal investigator $1,675,365.46 75
PY2021 Principal investigator $2,129,940.43 124
PY2020 Principal investigator $2,169,106.03 143
PY2019 Principal investigator $2,064,075.98 203

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

203 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $9,429.45 12/31/2019 Non-covered Recipient Entity
University Of Florida
MEDI9447 CD73 Solid Tmr-D6070C00001 Phase 1 Clinical Trial No dispute reported 06/30/2026 684995233
Principal investigator 1 AstraZeneca Pharmaceuticals LP $969.57 12/31/2019 Non-covered Recipient Entity
University Of Florida Health Womens Health Specialists
MEDI9447 CD73 Solid Tmr-D6070C00001 Phase 1 Clinical Trial No dispute reported 06/30/2026 684995267
Principal investigator 1 Seattle Genetics, Inc. $1,248.00 12/11/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678825077
Principal investigator 1 GlaxoSmithKline, LLC. $235,740.12 12/10/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
0000000000000000000000000000000000000000000000000000000000000000214456 No dispute reported 06/30/2026 965534673
Principal investigator 1 Amgen Inc. $6,064.00 11/27/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA HEALTH
AMG 510_P1/2 Monotherapy NSCLC/CRC/Tumor Agnostic_20170543. No dispute reported 06/30/2026 675795239
Principal investigator 1 Incyte Corporation $5,618.00 11/27/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436753
Principal investigator 1 Incyte Corporation $4,805.00 11/12/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436747
Principal investigator 1 Incyte Corporation $12,980.00 11/12/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436749
Principal investigator 1 Incyte Corporation $3,610.00 11/12/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436751
Principal investigator 1 Incyte Corporation $4.84 11/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436675
Principal investigator 1 Incyte Corporation $0.18 11/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436677
Principal investigator 1 Incyte Corporation $101.70 11/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436679
Principal investigator 1 Incyte Corporation $23.40 11/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436681
Principal investigator 1 Incyte Corporation $30.40 11/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436683
Principal investigator 1 Incyte Corporation $19.10 11/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436685
Principal investigator 1 Incyte Corporation $47.16 11/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436687
Principal investigator 1 Incyte Corporation $565.74 11/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436689
Principal investigator 1 Incyte Corporation $46.80 11/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436691
Principal investigator 1 Incyte Corporation $65.14 11/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436693
Principal investigator 1 Incyte Corporation $185.20 11/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436695
Principal investigator 1 Incyte Corporation $22.80 11/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436697
Principal investigator 1 Incyte Corporation $94.32 11/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436699
Principal investigator 1 Incyte Corporation $81.36 11/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436701
Principal investigator 1 Incyte Corporation $19.10 11/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436709
Principal investigator 1 Incyte Corporation $23.40 11/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436711
Principal investigator 1 Incyte Corporation $46.80 11/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436713
Principal investigator 1 Incyte Corporation $19.10 11/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436715
Principal investigator 1 Incyte Corporation $2,070.90 11/05/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 708436743
Principal investigator 1 Incyte Corporation $5,796.00 11/05/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 708436745
Principal investigator 1 GlaxoSmithKline, LLC. $171,447.36 10/23/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
0000000000000000000000000000000000000000000000000000000000000000214456 No dispute reported 06/30/2026 965534675
Principal investigator 1 TESARO, Inc. $24,828.76 10/23/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
UF-STO-ETI-001 THOMAS GEORGE No dispute reported 06/30/2026 689413731
Principal investigator 1 Merck Sharp & Dohme Corporation $1,553.10 10/21/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation HRRm and,or Homologous Recombination Deficiency HRD Positive Advanced Cancer No dispute reported 06/30/2026 691533243
Principal investigator 1 Seattle Genetics, Inc. $9,473.10 10/21/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678825079
Principal investigator 1 Merck Sharp & Dohme Corporation $246.69 10/16/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation HRRm and,or Homologous Recombination Deficiency HRD Positive Advanced Cancer No dispute reported 06/30/2026 691398215
Principal investigator 1 Merck Sharp & Dohme Corporation $246.69 10/16/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation HRRm and,or Homologous Recombination Deficiency HRD Positive Advanced Cancer No dispute reported 06/30/2026 691504003
Principal investigator 1 Incyte Corporation $64.00 10/10/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 708436755
Principal investigator 1 Incyte Corporation $64.00 10/10/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 708436757
Principal investigator 1 Incyte Corporation $44.80 10/10/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 708436759
Principal investigator 1 Incyte Corporation $18,850.50 10/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 708436741
Principal investigator 1 Seattle Genetics, Inc. $2,366.00 10/02/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678825075
Principal investigator 1 Amgen Inc. $4,109.51 09/24/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
AMG 510_P1/2 Monotherapy NSCLC/CRC/Tumor Agnostic_20170543. No dispute reported 06/30/2026 675795203
Principal investigator 1 Incyte Corporation $650.00 09/19/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 708436727
Principal investigator 1 Incyte Corporation $2,752.00 09/17/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 708436733
Principal investigator 1 Incyte Corporation $960.00 09/17/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 708436735
Principal investigator 1 Incyte Corporation $704.00 09/17/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 708436737
Principal investigator 1 Incyte Corporation $640.00 09/17/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 708436739
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $200.00 09/13/2019 Non-covered Recipient Entity
University Of Florida
Clinical Study Site Agreement No dispute reported 06/30/2026 629172715
Principal investigator 1 Incyte Corporation $15.20 09/10/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436599
Principal investigator 1 Incyte Corporation $3.08 09/10/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436601
Principal investigator 1 Incyte Corporation $0.27 09/10/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436603
Principal investigator 1 Incyte Corporation $70.74 09/10/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436605
Principal investigator 1 Incyte Corporation $61.02 09/10/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436607
Principal investigator 1 Incyte Corporation $34.20 09/10/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436609
Principal investigator 1 Incyte Corporation $11.70 09/10/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436611
Principal investigator 1 Incyte Corporation $9.55 09/10/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436613
Principal investigator 1 Incyte Corporation $45.60 09/10/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 708436631
Principal investigator 1 Incyte Corporation $30.40 09/10/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 708436633
Principal investigator 1 Incyte Corporation $35.10 09/10/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 708436635
Principal investigator 1 Incyte Corporation $70.50 09/10/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 708436637
Principal investigator 1 Incyte Corporation $60.15 09/10/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 708436639
Principal investigator 1 Incyte Corporation $28.65 09/10/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 708436641
Principal investigator 1 Incyte Corporation $117.90 09/10/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 708436643
Principal investigator 1 Incyte Corporation $45.60 09/10/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 708436659
Principal investigator 1 Incyte Corporation $35.10 09/10/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 708436661
Principal investigator 1 Incyte Corporation $15.20 09/10/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436663
Principal investigator 1 Incyte Corporation $11.70 09/10/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436665
Principal investigator 1 Incyte Corporation $15.20 09/10/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436667
Principal investigator 1 Incyte Corporation $11.70 09/10/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436669
Principal investigator 1 Incyte Corporation $9.55 09/10/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436671
Principal investigator 1 Incyte Corporation $11.70 09/10/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436673
Principal investigator 1 Incyte Corporation $11,208.60 09/05/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 708436725
Principal investigator 1 Seattle Genetics, Inc. $2,600.00 08/28/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678825039
Principal investigator 1 Merck Sharp & Dohme Corporation $500.00 08/14/2019 Non-covered Recipient Entity
UNVIERSITY OF FLORIDA
A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab With 5-FU in Participants with Unresectable or Metastatic Colorectal Cancer who Have not Progressed Following First-line Induction of FOLFOX With Bevacizumab LYNK-003. No dispute reported 06/30/2026 691456479
Principal investigator 1 Incyte Corporation $3.72 08/09/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy No dispute reported 06/30/2026 708436469
Principal investigator 1 Incyte Corporation $20.26 08/09/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy No dispute reported 06/30/2026 708436471
Principal investigator 1 Incyte Corporation $232.98 08/09/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy No dispute reported 06/30/2026 708436473
Principal investigator 1 Incyte Corporation $11.96 08/09/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy No dispute reported 06/30/2026 708436475
Principal investigator 1 Incyte Corporation $132.21 08/09/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy No dispute reported 06/30/2026 708436477
Principal investigator 1 Incyte Corporation $2.13 08/09/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy No dispute reported 06/30/2026 708436479
Principal investigator 1 Incyte Corporation $0.60 08/09/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy No dispute reported 06/30/2026 708436481
Principal investigator 1 Incyte Corporation $0.96 08/09/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy No dispute reported 06/30/2026 708436483
Principal investigator 1 Incyte Corporation $372.42 08/09/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy No dispute reported 06/30/2026 708436485
Principal investigator 1 Incyte Corporation $140.64 08/09/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy No dispute reported 06/30/2026 708436487
Principal investigator 1 Incyte Corporation $61.84 08/09/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy No dispute reported 06/30/2026 708436489
Principal investigator 1 Incyte Corporation $40.86 08/09/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy No dispute reported 06/30/2026 708436491
Principal investigator 1 Incyte Corporation $5.60 08/09/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy No dispute reported 06/30/2026 708436493
Principal investigator 1 Incyte Corporation $95.50 08/09/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy No dispute reported 06/30/2026 708436495
Principal investigator 1 Incyte Corporation $0.26 08/09/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy No dispute reported 06/30/2026 708436535
Principal investigator 1 Incyte Corporation $11.70 08/09/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy No dispute reported 06/30/2026 708436537
Principal investigator 1 Incyte Corporation $30.40 08/09/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy No dispute reported 06/30/2026 708436539
Principal investigator 1 Incyte Corporation $172.89 08/09/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy No dispute reported 06/30/2026 708436541
Principal investigator 1 Incyte Corporation $21.06 08/09/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy No dispute reported 06/30/2026 708436543
Principal investigator 1 Incyte Corporation $47.75 08/09/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy No dispute reported 06/30/2026 708436545
Principal investigator 1 Incyte Corporation $100.25 08/09/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy No dispute reported 06/30/2026 708436547
Principal investigator 1 Incyte Corporation $58.50 08/09/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy No dispute reported 06/30/2026 708436615
Principal investigator 1 Incyte Corporation $28.65 08/09/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy No dispute reported 06/30/2026 708436617
Principal investigator 1 Incyte Corporation $317.70 08/09/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy No dispute reported 06/30/2026 708436619
Principal investigator 1 Incyte Corporation $117.90 08/09/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy No dispute reported 06/30/2026 708436621
Principal investigator 1 Incyte Corporation $1,117.26 08/09/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy No dispute reported 06/30/2026 708436623
Principal investigator 1 Incyte Corporation $565.74 08/09/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy No dispute reported 06/30/2026 708436625
Principal investigator 1 Incyte Corporation $70.50 08/09/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy No dispute reported 06/30/2026 708436627
Principal investigator 1 Incyte Corporation $76.00 08/09/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy No dispute reported 06/30/2026 708436629
Principal investigator 1 Incyte Corporation $20.26 08/09/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy No dispute reported 06/30/2026 708436645
Principal investigator 1 Incyte Corporation $140.64 08/09/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy No dispute reported 06/30/2026 708436647
Principal investigator 1 Incyte Corporation $58.50 08/09/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy No dispute reported 06/30/2026 708436649
Principal investigator 1 Incyte Corporation $61.84 08/09/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy No dispute reported 06/30/2026 708436651
Principal investigator 1 Incyte Corporation $58.50 08/09/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy No dispute reported 06/30/2026 708436653
Principal investigator 1 Incyte Corporation $76.00 08/09/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy No dispute reported 06/30/2026 708436655
Principal investigator 1 Incyte Corporation $47.75 08/09/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy No dispute reported 06/30/2026 708436657
Principal investigator 1 Amgen Inc. $77.25 08/01/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
AMG 510_P1/2 Monotherapy NSCLC/CRC/Tumor Agnostic_20170543. No dispute reported 06/30/2026 675795201
Principal investigator 1 Incyte Corporation $320.00 07/25/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 708436731
Principal investigator 1 Seattle Genetics, Inc. $15,744.30 07/16/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678825043
Principal investigator 1 Incyte Corporation $2,758.00 07/11/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 708436729
Principal investigator 1 Incyte Corporation $260.00 07/02/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 708436723
Principal investigator 1 Seattle Genetics, Inc. $8,463.00 07/02/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678825045
Principal investigator 1 Incyte Corporation $3,200.00 06/11/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436719
Principal investigator 1 Incyte Corporation $2,464.00 06/11/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436721
Principal investigator 1 Incyte Corporation $111.12 06/10/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436443
Principal investigator 1 Incyte Corporation $650.00 06/04/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 708436717
Principal investigator 1 AstraZeneca Pharmaceuticals LP $296,598.34 06/01/2019 Non-covered Recipient Entity
National Surgical Adjuvant Breast And Bowel Project Foundation, Inc
A Phase II Study to Assess the Activity of PD-L1 Inhibition with Durvalumab after Chemo-Radiotherapy in Patients with Stage II-IV Microsatelite Stable (MSS) Rectal Cancer No dispute reported 06/30/2026 684986195
Principal investigator 1 Incyte Corporation $650.00 05/28/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 708436593
Principal investigator 1 Incyte Corporation $228.00 05/28/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 708436595
Principal investigator 1 Incyte Corporation $488.00 05/28/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 708436597
Principal investigator 1 AstraZeneca Pharmaceuticals LP $7,650.00 05/24/2019 Non-covered Recipient Entity
University Of Florida Health Womens Health Specialists
A Phase II Study of the Dual Immune Checkpoint Blockade with Durvalumab plus Tremelimumab Following Palliative Hypofractionated Radiation in Patients with Microsatellite Stable (MSS) Metastatic Colorectal Cancer Progressing on Chemotherapy No dispute reported 06/30/2026 684995237
Principal investigator 1 Incyte Corporation $607,078.75 05/23/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436583
Principal investigator 1 Incyte Corporation $9,315.00 05/23/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436585
Principal investigator 1 Incyte Corporation $5,766.00 05/23/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436587
Principal investigator 1 Incyte Corporation $3,844.00 05/23/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436589
Principal investigator 1 Incyte Corporation $4,461.00 05/23/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436591
Principal investigator 1 Seattle Genetics, Inc. $988.00 05/22/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678824985
Principal investigator 1 GlaxoSmithKline, LLC. $85,723.68 05/21/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
0000000000000000000000000000000000000000000000000000000000000000214456 No dispute reported 06/30/2026 965534677
Principal investigator 1 Incyte Corporation $3,764.70 05/21/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 708436581
Principal investigator 1 AstraZeneca Pharmaceuticals LP $15,583.60 05/15/2019 Non-covered Recipient Entity
University Of Florida Health Womens Health Specialists
MEDI9447 CD73 Solid Tmr-D6070C00001 Phase 1 Clinical Trial No dispute reported 06/30/2026 684995245
Principal investigator 1 Incyte Corporation $147.00 05/14/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436573
Principal investigator 1 Incyte Corporation $1,024.00 05/14/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436575
Principal investigator 1 Incyte Corporation $192.00 05/14/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436577
Principal investigator 1 Incyte Corporation $4,015.00 05/14/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436579
Principal investigator 1 Incyte Corporation $0.75 05/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436397
Principal investigator 1 Incyte Corporation $1.28 05/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436399
Principal investigator 1 Incyte Corporation $38.20 05/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436401
Principal investigator 1 Incyte Corporation $38.39 05/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436403
Principal investigator 1 Incyte Corporation $2.48 05/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436405
Principal investigator 1 Incyte Corporation $1.76 05/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436407
Principal investigator 1 Incyte Corporation $0.30 05/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436409
Principal investigator 1 Incyte Corporation $377.16 05/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436411
Principal investigator 1 Incyte Corporation $58.50 05/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436413
Principal investigator 1 Incyte Corporation $47.75 05/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436415
Principal investigator 1 Incyte Corporation $35.10 05/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436417
Principal investigator 1 Incyte Corporation $76.00 05/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436419
Principal investigator 1 Incyte Corporation $70.20 05/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436421
Principal investigator 1 Incyte Corporation $28.65 05/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436423
Principal investigator 1 Incyte Corporation $282.96 05/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436425
Principal investigator 1 Incyte Corporation $1.98 05/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436427
Principal investigator 1 Incyte Corporation $21.34 05/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436429
Principal investigator 1 Incyte Corporation $13.64 05/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436431
Principal investigator 1 Incyte Corporation $45.60 05/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436433
Principal investigator 1 Incyte Corporation $152.55 05/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436435
Principal investigator 1 Incyte Corporation $136.80 05/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436437
Principal investigator 1 Incyte Corporation $1.08 05/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436439
Principal investigator 1 Incyte Corporation $162.72 05/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436441
Principal investigator 1 Incyte Corporation $0.30 05/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436445
Principal investigator 1 Incyte Corporation $2.48 05/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436447
Principal investigator 1 Incyte Corporation $38.39 05/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436449
Principal investigator 1 Incyte Corporation $0.75 05/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436451
Principal investigator 1 Incyte Corporation $1.28 05/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436453
Principal investigator 1 Incyte Corporation $47.75 05/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436455
Principal investigator 1 Incyte Corporation $35.10 05/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436457
Principal investigator 1 Incyte Corporation $1.28 05/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436459
Principal investigator 1 Incyte Corporation $76.00 05/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436461
Principal investigator 1 Incyte Corporation $35.10 05/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436463
Principal investigator 1 Incyte Corporation $28.65 05/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436465
Principal investigator 1 Taiho Oncology, Inc. $3,743.00 04/25/2019 Non-covered Recipient Entity
University of Florida
TAS 120 No dispute reported 06/30/2026 681433259
Principal investigator 1 Seattle Genetics, Inc. $32,002.10 04/18/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678824983
Principal investigator 1 Seattle Genetics, Inc. $2,860.00 04/03/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678824975
Principal investigator 1 Seattle Genetics, Inc. $3,420.14 04/03/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678824977
Principal investigator 1 AstraZeneca Pharmaceuticals LP $27,950.00 03/29/2019 Non-covered Recipient Entity
University Of Florida Health Womens Health Specialists
A Phase II Study to Assess the Activity of PD-L1 Inhibition with Durvalumab after Chemo-Radiotherapy in Patients with Stage II-IV Microsatelite Stable (MSS) Rectal Cancer No dispute reported 06/30/2026 684995241
Principal investigator 1 Seattle Genetics, Inc. $260.00 03/27/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678824979
Principal investigator 1 Taiho Oncology, Inc. $1,902.00 03/21/2019 Non-covered Recipient Entity
University of Florida
TAS-102-107 No dispute reported 06/30/2026 681433193
Principal investigator 1 Taiho Oncology, Inc. $5,997.00 03/21/2019 Non-covered Recipient Entity
University of Florida
TAS-102-107 No dispute reported 06/30/2026 681433197
Principal investigator 1 Incyte Corporation $26,227.00 03/19/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 708436549
Principal investigator 1 Incyte Corporation $2,752.00 03/19/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 708436551
Principal investigator 1 Incyte Corporation $960.00 03/19/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 708436553
Principal investigator 1 Incyte Corporation $704.00 03/19/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 708436555
Principal investigator 1 Incyte Corporation $640.00 03/19/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 708436557
Principal investigator 1 Eli Lilly and Company $23,990.00 03/12/2019 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
RANDOMIZED, DOUBLE-BLIND, PHASE 2 STUDY OF RAMUCIRUMAB OR MERESTINIB OR PLACEBO PLUS CISPLATIN AND GEMCITABINE AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED OR METASTATIC BILIARY TRACT CANCER No dispute reported 06/30/2026 654298667
Principal investigator 1 Celgene Corporation $2,240.00 03/08/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase III Study - PANC-003 (BMS Study Number: CA139-P15) (ABI-007-PANC-003) No dispute reported 06/30/2026 675419521
Principal investigator 1 Merck Sharp & Dohme Corporation $2,030.08 03/07/2019 Non-covered Recipient Entity
UF DAVIS CANCER CENTER
A Phase III Study of Pembrolizumab vs Chemotherapy in Microsatellite Instability- High or Mismatched Repair Deficient Colorectal Carcinoma No dispute reported 06/30/2026 691325249
Principal investigator 1 Incyte Corporation $4,160.00 02/26/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 708436561
Principal investigator 1 Incyte Corporation $2,438.00 02/26/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 708436563
Principal investigator 1 Incyte Corporation $12,675.00 02/26/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 708436565
Principal investigator 1 Incyte Corporation $6,272.00 02/26/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436567
Principal investigator 1 Incyte Corporation $10,626.00 02/26/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436569
Principal investigator 1 Incyte Corporation $320.00 02/26/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436571
Principal investigator 1 Eli Lilly and Company $131.25 02/25/2019 Non-covered Recipient Entity
DERMATOLOGY INSTITUTE AND SKIN CARE
RANDOMIZED, DOUBLE-BLIND, PHASE 2 STUDY OF RAMUCIRUMAB OR MERESTINIB OR PLACEBO PLUS CISPLATIN AND GEMCITABINE AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED OR METASTATIC BILIARY TRACT CANCER No dispute reported 06/30/2026 654293703
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,500.00 02/21/2019 Non-covered Recipient Entity
University Of Florida
A Phase II Study of the Dual Immune Checkpoint Blockade with Durvalumab plus Tremelimumab Following Palliative Hypofractionated Radiation in Patients with Microsatellite Stable (MSS) Metastatic Colorectal Cancer Progressing on Chemotherapy No dispute reported 06/30/2026 684995207
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $29,512.00 02/20/2019 Non-covered Recipient Entity
University Of Florida Board Of Trustees
A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer No dispute reported 06/30/2026 639758213
Principal investigator 1 Merck Sharp & Dohme Corporation $12,456.96 01/29/2019 Non-covered Recipient Entity
UF DAVIS CANCER CENTER
A Phase III Study of Pembrolizumab vs Chemotherapy in Microsatellite Instability- High or Mismatched Repair Deficient Colorectal Carcinoma No dispute reported 06/30/2026 691311333
Principal investigator 1 Incyte Corporation $26,674.00 01/22/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 708436559
Principal investigator 1 Taiho Oncology, Inc. $1,952.00 01/22/2019 Non-covered Recipient Entity
University of Florida
TAS-102-107 No dispute reported 06/30/2026 681433195
Principal investigator 1 AstraZeneca Pharmaceuticals LP $151,556.97 01/16/2019 Non-covered Recipient Entity
University Of Florida
MEDI9447 CD73 Solid Tmr-D6070C00001 Phase 1 Clinical Trial No dispute reported 06/30/2026 684995216
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,500.00 01/11/2019 Non-covered Recipient Entity
University Of Florida
A Phase II Study to Assess the Activity of PD-L1 Inhibition with Durvalumab after Chemo-Radiotherapy in Patients with Stage II-IV Microsatelite Stable (MSS) Rectal Cancer No dispute reported 06/30/2026 684995211
Principal investigator 1 Seattle Genetics, Inc. $21,775.00 01/09/2019 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 678824973
Principal investigator 1 Merck Sharp & Dohme Corporation $3,114.24 01/08/2019 Non-covered Recipient Entity
UF DAVIS CANCER CENTER
A Phase III Study of Pembrolizumab vs Chemotherapy in Microsatellite Instability- High or Mismatched Repair Deficient Colorectal Carcinoma No dispute reported 06/30/2026 691311157